Filip joined Sopartec in 2015, bringing in over 2 decades of commercial experience in developing assets, market access and due diligence in the field of life sciences both at small size and leading companies in the sector.
Filip started his career in cardiovascular research co-leading a project to phase II clinical development. He subsequently joined the patent department of JNJ, where he was involved in multiple due diligences, one resulting in oncomethylome sciences (now MDX Health).
Filip continued his corporate career at Innogenetics for business development and licensing, where he was also appointed to head investor relations, Solvay Pharmaceuticals, and Abbott. Prior to joining SOPARTEC/VIVES his focus was predominantly on market analysis and defence of brands, some of which had annual sales >$1bn.
Filip sits on the Board of Aphea, Syndesi and Virovet
He received a Ph.D in pharmaceutical sciences from the University of Antwerp, a CEIPI degree in EU Patent Law from the University of Strasbourg and Business Administration at IPO Antwerp. He is author of more than 20 scientific publications, and inventor on different patents.